share_log

Earnings Call Summary | Fulgent Genetics(FLGT.US) Q4 2023 Earnings Conference

Earnings Call Summary | Fulgent Genetics(FLGT.US) Q4 2023 Earnings Conference

業績電話會議摘要 | Fulgent Genetics (FLGT.US) 2023 年第四季度業績會議
moomoo AI ·  02/28 11:43  · 電話會議

The following is a summary of the Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript:

以下是 Fulgent Genetics (FLGT) 2023 年第四季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Fulgent Genetics reported Q4 revenue of $70 million, an increase compared to Q4 2022's $68 million. The full-year revenue exceeded guidance, ending at $262 million, a 44% YoY increase.

  • A one-time non-cash goodwill impairment charge of $120 million was incurred due to sustained share price decline, impacting GAAP expenses that reached $176.4 million.

  • The non-GAAP operating expenses totalled $45.1 million.

  • The Adjusted EBITDA loss for Q4 was $6.8 million, an improvement compared to $15.1 million in Q4 2022.

  • Fulgent Genetics ended Q4 with around $848 million in cash, cash equivalents, and marketable securities, and projects a total revenue approximating $280 million in 2024, implying a 7% YoY core revenue growth.

  • Fulgent Genetics報告第四季度收入爲7,000萬美元,與2022年第四季度的6,800萬美元相比有所增加。全年收入超過預期,收於2.62億美元,同比增長44%。

  • 由於股價持續下跌,產生了1.2億美元的一次性非現金商譽減值費用,影響了達到1.764億美元的GAAP支出。

  • 非公認會計准則運營支出總額爲4,510萬美元。

  • 第四季度調整後的息稅折舊攤銷前利潤虧損爲680萬美元,與2022年第四季度的1,510萬美元相比有所改善。

  • Fulgent Genetics在第四季度末擁有約8.48億美元的現金、現金等價物和有價證券,並預計2024年的總收入約爲2.8億美元,這意味着核心收入同比增長7%。

Business Progress:

業務進展:

  • Fulgent is advancing its therapeutic development business, with FID-007 showing encouraging results in cancer trials and FID-002 IND application planned for year-end.

  • The company has introduced successful products like the Beacon expanded carrier screening panel and Beacon preconception panel and partnered with Cooper Surgical to offer exclusive newborn genetic screening panels.

  • There are plans to enhance operating margins in the anatomic pathology business unit and substantial technological investments for fostering innovation.

  • Despite anatomic pathology revenues facing pricing and contract rate challenges, Fulgent Genetics sees promise in precision diagnostics, identified as the highest growth area for 2024.

  • With around $150.7 million available, the company continues to commit to common stock repurchasing.

  • Fulgent正在推進其治療開發業務,FID-007 在癌症試驗中顯示出令人鼓舞的結果,計劃於年底進行的 FID-002 IND 申請。

  • 該公司推出了成功的產品,例如Beacon擴展載體篩查小組和Beacon孕前試劑盒,並與Cooper Surgical合作提供獨家的新生兒基因篩查試劑盒。

  • 計劃提高解剖病理學業務部門的營業利潤率,並進行大量技術投資以促進創新。

  • 儘管解剖學病理學收入面臨定價和合同費率挑戰,但Fulgent Genetics認爲精確診斷前景看好,精確診斷被確定爲2024年增長最快的領域。

  • 該公司擁有約1.507億美元的可用資金,繼續承諾回購普通股。

More details: Fulgent Genetics IR

更多詳情: 富爾根特遺傳學 IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論